(281)-719-8904 KenFaulkenberry@AAAMP.com

AbbVie (ABBV) Dividend Analyzer Analysis

by | Dividend Aristocrats, Dividend Champions

AbbVie Dividend

(updated 2/23/2018)

The AbbVie dividend has been paid continuously since 1924 and increased for 45 consecutive years; qualifying the company as a Dividend Aristocrat. (Technically AbbVie has only existed since 2013. For reasons beyond my understanding AbbVie has been allowed to use Abbott Labs (AbbVie was spun-off by Abbott) dividend record and is considered a Dividend Aristocrat.

Price: $118.75
Dividend Yield: 3.2%

Current Dividend: $3.84
Cash Flow From Operations (CFO) Per Share (ttm): $6.21
Free Cash Flow Per Share (ttm): $5.88

Market Capitalization: $189 B
Enterprise Value: $214 B

Dividend Analyzer Checklist

(updated February 2018)

Valuation Score (11/34 points)

Free Cash Flow Yield (ttm): 4.6% (11/17 points)
EV to EBIT (ttm): 22.4
EV to EBITDA (ttm): 20.0 (0/17 points)
Price to Sales Ratio (ttm): 6.4
Price to Book Value (ttm):  27.1
Price to Earnings Ratio (P/E) (ttm): 34

Profitability Score (13/33 points)

Operating Earnings Yield (ttm): 5.3% (5/15 points)
Net Income (ttm): $5309 M
Gross Profit (ttm): $21176 M
Total Assets: $68840 M
Gross Profitability Ratio = GP / Total Assets: 31% (8/18 points)
Cash Return On Invested Capital (CROIC)(tttm): 20%
Return on Invested Capital (ROIC): 12%

Dividend Safety Score (18/33 points)

Dividend Payout Ratio (ttm): 58%
Cash Dividend Payout Ratio (ttm): 47%  (8/12 points)
Net Financial Debt: $28241 M
Total Assets: $68840 M
Net Financial Debt / Total Assets: 41% (2/12 points)
Net Financial Debt to EBITDA (ttm): 363%
Piotroski Score (1-9) (TTM): (8/9 points)

TOTAL POINTS – (42/100) (50 is an average score)

Earnings Report: 1/27/18
Next Earnings Report: 4/27/18

Stay Updated All the Time!

DVB Analyzer Bundle: Dividend Analyzer Newsletter & Dividend Sortable Excel Spreadsheet

DVB Portfolio Bundle: Dividend Portfolio & Treasure Trove Twelve Newsletters

SPECIAL 4 For 1 Price: DVB Full Membership

Learn More

Rankings & Recommendations

(updated February 2018)

AbbVie is ranked #288 (out of 432) overall and #27 (out of 31) in the Healthcare Sector by the Dividend Analyzer.

 

Type of Investor / Recommendation

Large Diversified Dividend Portfolios / AVOID
Looking For Exposure to Healthcare  Sector / AVOID
Deep Value Investors / AVOID

Position Disclosures:
DVB Portfolio Stocks – None
AAAMP Global Value Portfolio – None
AAAMP Retirement Growth & Income Portfolio – None
AAAMP Treasure Trove Twelve Portfolio – None

Company Description

Sector: Healthcare
Industry: Drug Manufacturers – Major

AbbVie is a global, research-based biopharmaceutical company formed in 2013 (spin-off from Abbott Laboratories). The company’s mission is to use its expertise, dedicated people, and unique approach to innovation to develop and market advanced therapies that address some of the world’s greatest health challenges.

The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie has 23 billion in annual sales, employs more than 28,000 people worldwide, and markets medicines in more than 170 countries.

Source: AbbVie Company Website

Dividend Investing Without Emotional Bias

DVB Analyzer Bundle: Dividend Analyzer Newsletter & Dividend Sortable Excel Spreadsheet - $68/year

DVB Portfolio Bundle: Dividend Portfolio & Treasure Trove Twelve Newsletters - $68/year

SPECIAL 4 For 1 Price: DVB Full Membership: Both Bundles for $99/year

Learn More
Disclaimer: While Arbor Investment Planner has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of third-party information presented herein. The sole purpose of this analysis is information. Nothing presented herein is, or is intended to constitute investment advice. Consult your financial advisor before making investment decisions.
Share This